Cargando…

Flow Cytometric Immune Profiling in Infliximab-Associated Tuberculosis

Tumor necrosis factor α antagonists are increasingly used to treat inflammatory and autoimmune disorders and are associated with increased risk of active tuberculosis. Diagnosis of active tuberculosis in patients taking tumor necrosis factor α antagonists can be challenging owing to increased incide...

Descripción completa

Detalles Bibliográficos
Autores principales: Pennington, Kelly, Sasieta, Humberto C, Ramos, Guiherme P, Erskine, Courtney L, Van Keulen, Virginia P, Peikert, Tobias, Escalante, Patricio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574471/
https://www.ncbi.nlm.nih.gov/pubmed/28890660
http://dx.doi.org/10.1177/1179547617724776
Descripción
Sumario:Tumor necrosis factor α antagonists are increasingly used to treat inflammatory and autoimmune disorders and are associated with increased risk of active tuberculosis. Diagnosis of active tuberculosis in patients taking tumor necrosis factor α antagonists can be challenging owing to increased incidence of extrapulmonary manifestations and false-negative results on current available diagnostic tests. We present a case of a young woman on infliximab for ulcerative colitis who presented with disseminated tuberculosis. As part of a research study, we performed flow cytometric immune profiling, which has previously not been reported in patients with active tuberculosis taking tumor necrosis α antagonists. The flow cytometry results were within the positive thresholds for tuberculosis infection. Flow cytometric immune profiling may be a valid diagnostic tool for patients taking tumor necrosis factor α antagonists.